-
公开(公告)号：US12220455B2
公开(公告)日：2025-02-11
申请号：US18345893
申请日：2023-06-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Sean Michael Sullivan , Daiki Matsuda , Kiyoshi Tachikawa , Padmanabh Chivukula , Priya Prakash Karmali , Jared Henry Davis , Yanjie Bao , Amit Sagi
IPC: A61K39/215 , A61K9/51 , A61K38/00 , A61K39/00 , A61K39/12 , A61K47/10 , A61K47/20 , A61K47/26 , C07K14/005 , C07K14/18 , C12N7/00 , C12N15/86
Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
-
公开(公告)号：US12070509B2
公开(公告)日：2024-08-27
申请号：US17246558
申请日：2021-04-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Daiki Matsuda , Padmanabh Chivukula , Priya Prakash Karmali , Yanjie Bao , Jerel Boyd Lee Vega , Rajesh Mukthavaram , Amit Sagi
CPC classification number: A61K48/0033 , A61K48/005 , A61P11/00 , C07K14/4702
Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.
-
公开(公告)号：US11939363B2
公开(公告)日：2024-03-26
申请号：US17812576
申请日：2022-07-14
Applicant: ARCTURUS THERAPEUTICS, INC.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Padmanabh Chivukula , Daiki Matsuda , Arisa Cale
IPC: C07K14/505 , A61K31/7115 , A61K38/17 , A61K38/18 , A61K38/48 , C07K14/575 , C07K14/745 , C07K14/81 , A61K38/00 , C12Q1/68
CPC classification number: C07K14/505 , A61K31/7115 , A61K38/1709 , A61K38/1816 , A61K38/482 , A61K38/4846 , C07K14/575 , C07K14/745 , C07K14/81 , A61K38/00
Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
-
公开(公告)号：US20230219996A1
公开(公告)日：2023-07-13
申请号：US17816243
申请日：2022-07-29
Applicant: Arcturus Therapeutics, Inc.
Inventor： Daiki MATSUDA , Sean Michael Sullivan , Kiyoshi Tachikawa , Padmanabh Chivukula , Priya Prakash Karmali , Yanjie Bao , Amit Sagi , Rajesh Mukthavaram
CPC classification number: C07H21/02 , A61K9/19 , A61K9/127 , A61K47/14 , A61K47/28 , C07K14/11 , C07K14/165 , C07K14/1808
Abstract: Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.
-
公开(公告)号：US11407800B2
公开(公告)日：2022-08-09
申请号：US15907123
申请日：2018-02-27
Applicant: Arcturus Therapeutics, Inc.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Padmanabh Chivukula , Daiki Matsuda , Arisa Cale
IPC: C12N15/10 , C07K14/505 , C07K14/745 , C07K14/575 , C07K14/81 , A61K38/48 , A61K38/17 , A61K38/18 , A61K31/7115 , A61K38/00
Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
-
Patent Agency Ranking
公开(公告)号：US20220023442A1
公开(公告)日：2022-01-27
申请号：US17246558
申请日：2021-04-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Daiki Matsuda , Padmanabh Chivukula , Priya Prakash Karmali , Yanjie Bao , Jerel Boyd Lee Vega , Rajesh Mukthavaram , Amit Sagi
Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.
-
公开(公告)号：US10683500B2
公开(公告)日：2020-06-16
申请号：US16109231
申请日：2018-08-22
Applicant: Arcturus Therapeutics, Inc.
Inventor： Kiyoshi Tachikawa , Joseph E. Payne , Padmanabh Chivukula
IPC: C12N15/113 , A61K31/713 , A61K47/14
Abstract: This invention provides UNA oligomers for gene silencing with reduced off-target effects. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and various nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis with reduced off-target effects by administering a UNA oligomer to a subject.
-
公开(公告)号：US20180327471A1
公开(公告)日：2018-11-15
申请号：US15907123
申请日：2018-02-27
Applicant: Arcturus Therapeutics, Inc.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Padmanabh Chivukula , Daiki Matsuda , Arisa Cale
IPC: C07K14/505 , C07K14/745 , C07K14/81 , C07K14/575
CPC classification number: C07K14/505 , A61K31/7088 , A61K31/7105 , A61K35/545 , A61K38/00 , A61K38/17 , C07K14/575 , C07K14/745 , C07K14/81
Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. This invention also provides processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein.
-
公开(公告)号：US20170137821A1
公开(公告)日：2017-05-18
申请号：US15410984
申请日：2017-01-20
Applicant: Arcturus Therapeutics, Inc.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Christine Esau , Padmanabh Chivukula
IPC: C12N15/113 , A61K9/127
CPC classification number: C12N15/1131 , A61K9/1271 , A61K47/6911 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/323 , C12N2310/344 , C12N2310/3515 , C12N2320/32
Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.
-
公开(公告)号：US20160130567A1
公开(公告)日：2016-05-12
申请号：US14929366
申请日：2015-11-01
Applicant: Arcturus Therapeutics, Inc.
Inventor： Padmanabh Chivukula , Luigi Warren , Kiyoshi Tachikawa , Joseph E. Payne
IPC: C12N9/10 , C07K14/505 , C07K14/81 , C07K14/705 , C12N9/88 , C12N9/24 , C07K14/575 , C07K14/47 , C12N9/12 , C07K14/445 , C07K14/005 , C12N9/64 , C12N9/02
CPC classification number: C12N9/1018 , A61K39/00 , A61K48/00 , C07K14/445 , C07K14/463 , C07K14/47 , C07K14/4712 , C07K14/4717 , C07K14/505 , C07K14/524 , C07K14/575 , C07K14/705 , C07K14/745 , C07K14/805 , C07K14/8125 , C12N9/0071 , C12N9/1051 , C12N9/1205 , C12N9/2451 , C12N9/644 , C12N9/88 , C12N2740/16222 , C12N2840/105 , C12N2840/60 , C12Y114/16001 , C12Y201/03003 , C12Y204/01025 , C12Y207/0104 , C12Y302/01033 , C12Y304/21022 , C12Y403/02001
Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.
Abstract translation: 本发明提供一系列可翻译的信使UNA（mUNA）分子。 可以在体外和体内翻译mUNA分子以提供活性多肽或蛋白质，或提供免疫剂或疫苗组分。 mUNA分子可用作活性剂以在细胞或受试者中表达活性多肽或蛋白质。 其中，mUNA分子可用于治疗罕见疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.028 seconds)
